Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Felbamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felbamate SCHEMBL34947 | 1.00 | CYP1A2 (1.00) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL17597519 | 0.98 | CYP1A2 (0.96) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL7153063 | 0.98 | CYP1A2 (0.96) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL1049127 | 0.93 | CYP1A2 (0.86) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8392182 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8392180 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8056124 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL14979788 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8089944 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL7775772 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3193852-A1 | NMDA RECEPTOR ANTAGONISTS FOR TREATING GAUCHER DISEASE | Yeda Research and Development Co., Ltd. (IL) | 2017-07-26 | — | — | EP | disclosed |
| US-9539216-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same | INNERCAP TECHNOLOGIES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160136100-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | INNERCAP TECHNOLOGIES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016038616-A1 | NMDA RECEPTOR ANTAGONISTS FOR TREATING GAUCHER DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-17 | — | — | WO | disclosed |
| US-9241911-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same | INNERCAP TECHNOLOGIES, INC. | 2016-01-26 | — | — | US | disclosed |
| US-20140212482-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | INNERCAP TECHNOLOGIES, INC. | 2014-07-31 | — | — | US | disclosed |
| US-7670612-B2 | Supplying active materials in various phases in single dosage multicompartment capsule | INNERCAP TECHNOLOGIES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |